Research Topics
Genomes and Genes | Edward P GelmannSummaryAffiliation: Georgetown University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Searching for the gatekeeper oncogene of prostate cancerEdward P Gelmann
Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, 3800 Reservoir Rd NW, 20007 2197, Washington, DC, USA
Crit Rev Oncol Hematol 46:S11-20. 2003....- Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein functionEdward P Gelmann
Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007 2197, USA
Cancer Res 62:2654-9. 2002..1 We conclude that the polymorphic NKX3.1 allele codes for a variant protein with altered DNA binding activity that may affect prostate cancer risk... - Expression of genes and proteins specific for prostate cancerEdward P Gelmann
Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20057, USA
J Urol 172:S23-6; discussion S26-7. 2004..We reviewed the pertinent literature and discuss high throughput approaches to the identification of molecular markers characteristic of prostate cancer... - Expression of NKX3.1 in normal and malignant tissuesEdward P Gelmann
Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia 20007 2197, USA
Prostate 55:111-7. 2003..NKX3.1, a member of the NK-class of homeodomain proteins, is expressed primarily in the adult prostate and has growth suppression and differentiating effects in prostate epithelial cells... 
NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferationErin Muhlbradt
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA
Cancer Res 69:2615-22. 2009..Thus, there is a close relationship in vitro and in vivo between NKX3.1 and IGFBP-3. The growth-suppressive effects of NKX3.1 in prostate cells are mediated, in part, by activation of IGFBP-3 expression...- NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activityCai Bowen
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007 2197, USA
Cancer Res 67:455-64. 2007..This is the first report that a homeodomain protein can modify the activity of Topo I and may have implications for organ-specific DNA replication, transcription, or DNA repair... - Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptorLiang Nian Song
Department of Oncology, Lombardi Cancer Center, Georgetown University, 3800 Reservoir Road, Northwest, Washington, D C 20057, USA
Mol Endocrinol 18:70-85. 2004..Mifepristone also antagonized R1881 action on the growth of LNCaP prostate cancer cells... - Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factorJeong Ho Ju
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW, Washington, DC 20007, USA
J Mol Biol 360:989-99. 2006..1 and SRF was demonstrated by targeted mutagenesis of an NKX3.1 expression vector in a SMGA reporter assay. The results implicate the NKX3.1 N-terminal region in regulation of transcriptional activity of this tumor suppressor... - Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland sizeElizabeth Rodriguez Ortner
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007 2197, USA
Urology 67:311-5. 2006..1 prostate homeobox gene. The polymorphism, found in 10% of the population, affects the NKX3.l protein by replacing a cysteine for arginine at amino acid 52 and alters protein phosphorylation and DNA binding... - Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrenceHongzhen Li
Department of Oncology and Biostatistics Unit, Lombardi Comprehensive Cancer Center, Georgetown, University Medical Center, Washington, District of Columbia 20057, USA
Clin Cancer Res 11:5863-8. 2005..Here, we investigated whether activation of Stat5 in prostate cancer was linked to clinical outcome with disease recurrence as end point... - Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptorLiang Nian Song
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007 2197, USA
J Biol Chem 280:37853-67. 2005..We propose that beta-catenin may play an integral role in formation of the androgen-receptor transcriptional complex... 
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcriptionLiang Nian Song
Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, D C 20007 2197, USA
Mol Cell Biol 23:1674-87. 2003..Taken together, the data show that beta-catenin can bind to the androgen receptor LBD and modulate the effects of the androgen receptor NTD and TIF2 on transcription...- Targeted therapies for prostate cancerEkatherine Asatiani
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW Washington, DC 20007-2197, USA
Expert Opin Ther Targets 9:283-98. 2005..The interaction of signal kinase inhibitors with androgen ablation and with cytotoxic chemotherapy remains to be explored... - Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancerEkatherine Asatiani
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA
Cancer Res 65:1164-73. 2005..Samples with protein expression below the median level in cancer cells had both NKX3.1 deletion and selective CpG methylation... - Molecular biology of prostate-cancer pathogenesisRandi L Shand
Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA
Curr Opin Urol 16:123-31. 2006..The final common pathway after androgen ablation appears to be activation of androgen receptor... - P53 gene mutations: case study of a clinical marker for solid tumorsMinetta C Liu
Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
Semin Oncol 29:246-57. 2002.... - Retinoblastoma protein-mediated apoptosis after gamma-irradiationCai Bowen
Department of Medicine, Lombardi Cancer Center, Georgetown University, Washington, DC 20007-2197, USA
J Biol Chem 277:44969-79. 2002..In addition, p38 MAPK activation occurred independent of RB. ABL kinase, JUN N-terminal kinase, and p38 MAPK activity were all required for RB-mediated DU-145 cell death after gamma-irradiation... - The ubiquitin-proteasome pathway and its role in cancerAparna Mani
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20007-2197, USA
J Clin Oncol 23:4776-89. 2005..Further work in this area holds great promise toward our understanding and treatment of a wide range of cancers... - Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trialE David Crawford
Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
J Urol 175:1286-90; discussion 1290. 2006..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States... - Role of cadmium in the regulation of AR gene expression and activityMary Beth Martin
Department of Biochemistry and Molecular Biology, Lombardi Cancer Center, E411 Research Building, 3970 Reservoir Road NW, Washington, D.C. 20007
Endocrinology 143:263-75. 2002..97- to 3-fold) and the seminal vesicle complex (approximately 1.5-fold) and increased the expression of the androgen-regulated gene, probasin (27-fold). The in vivo effects were also blocked by an antiandrogen... - Cross-regulation of signaling pathways: an example of nuclear hormone receptors and the canonical Wnt pathwayMarcy E Beildeck
Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road, NW, Washington, DC 20057, USA
Exp Cell Res 316:1763-72. 2010..The aim of this review is to demonstrate the importance of considering pathway cross-talk when predicting functional outcomes of signaling, using nuclear hormone receptor/canonical Wnt pathway cross-talk as an example... - Molecular biology of the androgen receptorEdward P Gelmann
Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, 3800 Reservoir Rd NW, Washington, DC 20007 2197, USA
J Clin Oncol 20:3001-15. 2002..Further understanding of AR action and new strategies to interfere with AR signaling hold promise for improving prostate cancer therapy... - 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901Asim Amin
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
Urol Oncol 22:398-403. 2004..9-nitrocamptothecin (9-NC) a novel, oral camptothecin analogue was tested as second line chemotherapy for patients with progressive hormone refractory prostate cancer... - Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organizationYing Zhang
Department of Oncology, Lombardi Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC 20007, USA
Cancer 100:300-7. 2004..The impact of radical prostatectomy on survival remains to be demonstrated... - The impact of item order on ratings of cancer risk perceptionKathryn L Taylor
Lombardi Cancer Center, Georgetown University, Washington DC 20007-4104, USA
Cancer Epidemiol Biomarkers Prev 11:654-9. 2002..Although the use of multiple items may provide more information than when only a single method is used, different conclusions may be reached depending on the context in which an item is assessed... - Complexities of prostate-cancer riskEdward P Gelmann
N Engl J Med 358:961-3. 2008 - A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormonesMary Ellen Taplin
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
BJU Int 101:1084-9. 2008..To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites.. - Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trialPaul F Pinsky
Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
BJU Int 99:775-9. 2007..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy... - Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cellsShyh Han Tan
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Cancer Res 68:236-48. 2008..The work presented here provides the first evidence of synergy between AR and the prolactin signaling protein Stat5a/b in human prostate cancer cells... - Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1Mark C Markowski
Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
Cancer Res 68:6896-901. 2008..Our data suggest that strategies to inhibit inflammation or to inhibit effector kinases may be useful approaches to prostate cancer prevention... - Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and functionS Lilly Zheng
Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
Cancer Res 66:69-77. 2006..These results suggest that germ-line sequence variants in NKX3.1 may play a role in susceptibility to hereditary prostate cancer and underscore a role for NKX3.1 as a prostate cancer gatekeeper... - Silencing mediator for retinoid and thyroid hormone receptor and nuclear receptor corepressor attenuate transcriptional activation by the beta-catenin-TCF4 complexLiang Nian Song
Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032, USA
J Biol Chem 283:25988-99. 2008..These findings demonstrate an important role for corepressors SMRT and NCoR in the regulation of beta-catenin-TCF4-mediated gene transcription... - Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trialUlrike Peters
Cancer Prevention Program, Fred Hutchinson Cancer Research Center, P O Box 19024, 1100 Fairview Avenue North M4 B402, Seattle, WA 98109 1024, USA
Cancer Epidemiol Biomarkers Prev 16:962-8. 2007..This has stimulated extensive laboratory and clinical research, as well as much commercial and public enthusiasm. However, the epidemiologic evidence remains inconclusive... - Genome-wide association study of prostate cancer identifies a second risk locus at 8q24Meredith Yeager
SAIC Frederick, National Cancer Institute NCI Frederick Cancer Research and Development Center, Frederick, Maryland 21702, USA
Nat Genet 39:645-9. 2007..We estimate that the population attributable risk of the new locus, marked by rs6983267, is higher than the locus marked by rs1447295 (21% versus 9%)... - Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancerTobias Zellweger
Department of Urology, University of Basel, , 4031 Basel, Switzerland
Prostate 55:20-9. 2003..We identified syndecan-1 as a new prognostic factor and provide evidence for an androgen-dependent regulation of CD-10 expression... - Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and TreatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 172:S3-5. 2004 - Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trialGerald L Andriole
Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
J Natl Cancer Inst 97:433-8. 2005..We describe the population enrolled in the PLCO trial, their baseline PSA and DRE screening results, and diagnostic follow-up results during the first year of follow-up... - Methods for etiologic and early marker investigations in the PLCO trialRichard B Hayes
Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS 8114, Bethesda, MD 20892, USA
Mutat Res 592:147-54. 2005..g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial...